What Hims & Hers stock could be witnessing now is a short-squeeze. As its stock began rising sharply, short-sellers move to get out. So over the past week, we’ve seen shares surge 60%. In midday ...

GLP-1 and nutrition: managing risks for at-risk patients. Dr Almandoz shares key insights on malnutrition risks in post-bariatric and older patients, plus how to tailor care for better outcomes.

Popular weight-loss therapies like Novo Nordisk's Wegovy and Eli Lilly's Zepbound result in both fat and muscle loss.

GLP-1s and nutrition: quality over restriction! Dr Almandoz shares how shifting from restrictive diets to evidence-based, ...

In this article, we will look at the 10 Best Performing Healthcare Stocks So Far in 2025.

A new case study is the latest to suggest that GLP-1 therapy can tamp down people's unhealthy cravings of drugs like alcohol ...

Several local companies are developing technologies that they hope could replace a painful poke with something that feels more like having Velcro against your skin for a few minutes.

A new clinical trial showed promising results in curbing alcohol cravings in individuals with moderate alcohol-use disorder.

Commercials run by the telehealth company Hims & Hers have been placed under the microscope as lawmakers are calling out advertisement of prescription of injectable weight-loss drugs without ...

Ascletis Pharma’s rapid-fire expansion into obesity drug development has passed another milestone. | Ascletis Pharma’s ...

Manufacturers such as Nestle have responded, debuting its Vital Pursuit brand specifically designed to support GLP-1 consumer diets. The frozen food products initially launched in September and ...

Hims & Hers is expanding its offerings through the Trybe Labs deal after it added compounded weight loss drugs.